Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de PIT565 em Malignidades de Células B Recidivantes e/ou Refratárias

18 de novembro de 2026 atualizado por: Novartis Pharmaceuticals

Um estudo de fase I, aberto e multicêntrico de PIT565 em pacientes com neoplasias de células B recidivantes e/ou refratárias

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This is an open-label, multicenter, phase I study of PIT565 in patients with R/R B-NHL and R/R B-ALL.

The study comprises a dose escalation part of PIT565 in two independent groups (group A: R/R B-NHL and B: R/R B-ALL) and a dose expansion part in three independent groups (R/R large B-cell lymphoma (LBCL) randomized in 1:1 ratio to two RDs (A1 and A2), and R/R B-ALL (B1)).

During the dose escalation, the safety (including the dose-dose limiting toxicity (DLT) relationship) and tolerability of PIT565 will be assessed, and schedule(s), route(s) of administration and dose(s) will be identified for use in the expansion part based on the review of these data. The RD will also be guided by the available information on pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity. The dose escalation will be guided by an adaptive Bayesian logistic regression model (BLRM) following the Escalation with Overdose Control (EWOC) principle.

Different schedules and routes of administrations will be explored in the dose escalation groups.

The dose expansion will further explore the MTD(s) and/or RD(s) and the selected schedule(s) and route of administration(s) in the three patients' groups.

Tipo de estudo

Intervencional

Inscrição (Real)

61

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Ghent, Bélgica, 9000
        • Novartis Investigative Site
      • Beijing, China, 100730
        • Novartis Investigative Site
      • Shanghai, China, 200032
        • Novartis Investigative Site
      • Tianjin, China, 300020
        • Novartis Investigative Site
      • Singapore, Cingapura, 119074
        • Novartis Investigative Site
      • Singapore, Cingapura, 169608
        • Novartis Investigative Site
      • Barcelona, Espanha, 08035
        • Novartis Investigative Site
      • Barcelona, Espanha, 08036
        • Novartis Investigative Site
    • Florida
      • Miami, Florida, Estados Unidos, 33136
        • University Of Miami
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago Medical Center
    • Kansas
      • Fairway, Kansas, Estados Unidos, 66205
        • The University of Kansas Clinical Research Ctr
    • New York
      • New York, New York, Estados Unidos, 10065
        • Memorial Sloan Kettering Cancer Ctr
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Oregon Health Sciences University
      • Créteil, França, 94010
        • Novartis Investigative Site
      • Marseille, França, 13273
        • Novartis Investigative Site
      • Tel Aviv, Israel, 6423906
        • Novartis Investigative Site
    • RE
      • Reggio Emilia, RE, Itália, 42123
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Japão, 2778577
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 100 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study.
  • Male or female patients ≥18 years of age at the date of signing the informed consent form
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2

NHL patient population

  • Refractory or relapsed B-NHL
  • Must have relapsed after or failed to respond to at least two prior treatment therapies including an αCD20 monoclonal antibody containing chemotherapy combination regimen
  • Must have at least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan

ALL patient population

  • Refractory or relapsed CD19-positive B-ALL
  • Morphologic disease in the bone marrow (≥ 5% blasts)

Exclusion Criteria:

  • History of severe hypersensitivity to any ingredient of the study treatment or its excipients
  • Contraindication to tocilizumab
  • History of ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
  • Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type
  • Active central nervous system (CNS) involvement by malignancy or presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within the 2 weeks prior to the start of study treatment
  • Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur
  • Patients receiving systemic treatment with any immunosuppressive medication

Other protocol-defined inclusion/exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: PIT565 Group A (dose escalation part)

PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Experimental: PIT565 Group B (dose escalation part)

PIT565 in adult R/R ALL patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Experimental: PIT565 Group A1 (dose expansion part)

PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Experimental: PIT565 Group A2 (dose expansion part)

PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Experimental: PIT565 Group B1 (dose expansion part)

PIT565 in adult R/R ALL patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence and severity of Dose Limiting Toxicities (DLTs)
Prazo: 28 days or 35 days, depending on the dosing schedule

Assessment of safety of study drug. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of CTCAE grade 3 or higher that occurs within the DLT evaluation period (28 days or 35 days depending on the schedule) and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with exceptions provided in the clinical protocol.

28 days or 35 days, depending on the dosing schedule
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: 21 months

Assessment of safety of study drug.

21 months
Frequency of dose interruptions
Prazo: 21 months

Assessment of tolerability of study drug

21 months
Frequency of dose reductions
Prazo: 21 months

Assessment of tolerability of study drug

21 months
Dose intensities
Prazo: 21 months

Assessment of tolerability of study drug Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure.

21 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall Response Rate (ORR)
Prazo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Complete Response (CR) rate
Prazo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Best Overall Response (BOR)
Prazo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Duration Of Response (DOR)
Prazo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Overall Survival (OS)
Prazo: 33 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

33 months
Progression Free Survival (PFS)
Prazo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Event-free survival (EFS)
Prazo: 21 months

Evaluation of anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Maximum concentration of PIT565 (Cmax)
Prazo: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Area Under the Curve of PIT565 (AUC)
Prazo: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Trough concentration of PIT565 (C trough)
Prazo: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Prevalence of Anti-drug antibodies (ADA) at baseline
Prazo: Baseline

Assessment of anti-PIT565 antibodies in serum.

Baseline
Incidence of Anti-drug antibodies (ADA) on treatment
Prazo: 21 months

Assessment of anti-PIT565 antibodies in serum.

21 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de outubro de 2022

Conclusão Primária (Estimado)

31 de maio de 2027

Conclusão do estudo (Estimado)

31 de maio de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

25 de maio de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de maio de 2022

Primeira postagem (Real)

31 de maio de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CPIT565A12101
  • 2022-000367-45 (Número EudraCT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .